Skip to content

APRE

Aprea Therapeutics, Inc.

NASDAQ · Healthcare · Biotechnology · US

$0.79
−1.49%
Ask drillr
0
Insider buys (3m)
0
Insider sells (3m)
$0.00
Net value (3m)
+7.4%
Price return (3m)
Form 4 filings
DateInsiderActivitySharesPrice
Jun 17, 2026BIZZARI JEAN-PIERRE · directorA-Award3,135$0.00
Jun 17, 2026Duey Marc · directorA-Award3,135$0.00
Jun 17, 2026Duey Marc · directorA-Award12,555$0.73
Jun 17, 2026Pamukcu Rifat · directorA-Award3,135$0.00
Jun 17, 2026Pamukcu Rifat · directorA-Award12,555$0.73
Jun 17, 2026Seizinger Bernd R. · directorA-Award3,135$0.00
Jun 17, 2026Seizinger Bernd R. · directorA-Award12,555$0.73
Jun 17, 2026Grissinger Michael · directorA-Award3,135$0.00
Jun 17, 2026Peters Richard · directorA-Award3,135$0.00
Jun 17, 2026Gruia Gabriela · directorA-Award12,555$0.73
Jun 17, 2026Gruia Gabriela · directorA-Award3,135$0.00
Jun 17, 2026Grissinger Michael · directorA-Award12,555$0.73
Jun 17, 2026Peters Richard · directorA-Award12,555$0.73
Jun 17, 2026HENNEMAN JOHN B III · directorA-Award3,135$0.00
Jun 17, 2026HENNEMAN JOHN B III · directorA-Award12,555$0.73
Jun 17, 2026BIZZARI JEAN-PIERRE · directorA-Award12,555$0.73
Mar 16, 2026Hamill John P. · officer: SrVP/CFO/Prin Fin & Acct OfcrA-Award40,380$0.77
Mar 16, 2026Gilad Oren · director, officer: President/CEOA-Award80,700$0.77
Mar 16, 2026Gilad Oren · director, officer: President/CEOA-Award20,175$0.00
Mar 16, 2026Hamill John P. · officer: SrVP/CFO/Prin Fin & Acct OfcrA-Award10,095$0.00
Feb 2, 2026Hamill John P. · officer: SrVP/CFO/Prin Fin & Acct OfcrPurchase5,700$0.89
Feb 2, 2026Gilad Oren · director, officer: President/CEOPurchase28,100$0.89
Dec 11, 2025Gilad Oren · director, officer: President/CEOPurchase21,459$0.00
Dec 11, 2025Duey Marc · directorPurchase21,459$1.17
Dec 11, 2025Hamill John P. · officer: SrVP/CFO/Prin Fin & Acct OfcrPurchase5,000$1.17
Jun 9, 2025Grissinger Michael · directorA-Award4,185$1.81
Jun 9, 2025Pamukcu Rifat · directorA-Award1,045$0.00
Jun 9, 2025Pamukcu Rifat · directorA-Award4,185$1.81
Jun 9, 2025HENNEMAN JOHN B III · directorA-Award1,045$0.00
Jun 9, 2025HENNEMAN JOHN B III · directorA-Award4,185$1.81
Institutional positioning

13F filings over the trailing two quarters

New 8Increased 4Reduced 5Sold out 22
FilerActionSharesFiled
AIGH CAPITAL MANAGEMENT LLCIncreased1,015,541Apr 30, 2026
VESTAL POINT CAPITAL, LPNew Position350,000May 15, 2026
SPHERA FUNDS MANAGEMENT LTD.Unchanged270,000May 15, 2026
NANTAHALA CAPITAL MANAGEMENT, LLCUnchanged205,760May 15, 2026
GEODE CAPITAL MANAGEMENT, LLCIncreased119,131May 15, 2026
SCIENTECH RESEARCH LLCNew Position60,281May 15, 2026
CITADEL ADVISORS LLCNew Position58,600Sep 2, 2026
BNP PARIBAS ARBITRAGE, SNCIncreased39,817May 12, 2026
VANGUARD FIDUCIARY TRUST CONew Position38,464May 8, 2026
RENAISSANCE TECHNOLOGIES LLCNew Position25,100May 14, 2026
MORGAN STANLEYReduced22,330May 15, 2026
LPL FINANCIAL LLCReduced21,052May 6, 2026
VANGUARD CAPITAL MANAGEMENT LLCNew Position19,622May 15, 2026
HIGHTOWER ADVISORS, LLCUnchanged13,864May 5, 2026
TWO SIGMA SECURITIES, LLCNew Position13,500May 15, 2026

Insider activity from SEC Form 4; institutional positioning from 13F filings · Latest filing Jun 17, 2026